Stock Reports
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s...
MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics...
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why...
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research...
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders...
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus....
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials,...
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of...
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind...
This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon....